Hepatitis B virus surface antigen nanobody adsorbent, its preparation method and application

The preparation of hepatitis B virus surface antigen nanobody adsorbents using an Escherichia coli prokaryotic expression system solves the problem of high production costs for monoclonal antibodies, achieves efficient HBsAg adsorption and a simplified preparation process, reduces production costs and increases the possibility of commercialization.

CN116478279BActive Publication Date: 2026-11-17WUHAN RUIFA MEDICAL DEVICES CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202111677693.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-12-31
Publication Date
2026-11-17
Estimated Expiration
2041-12-31

AI Technical Summary

Technical Problem

In existing technologies, monoclonal antibody production costs are high, making it difficult to commercialize hepatitis B virus surface antigen adsorbents. Furthermore, traditional antibody preparation processes are complex and costly.

Method used

A single-domain antibody with the variable region of the heavy chain of an anti-HBsAg monoclonal antibody was prepared using an Escherichia coli prokaryotic expression system. This antibody was then covalently coupled to an adsorbent carrier to prepare a hepatitis B virus surface antigen nanobody adsorbent. The sequence of the variable region of the heavy chain of the anti-HBsAg humanized monoclonal antibody was optimized, and the vector was constructed and expressed using a GST-tagged pGEX-6P-1 vector.

Benefits of technology

It reduces production costs, increases the commercialization potential of adsorbents, ensures high HBsAg adsorption efficiency, simplifies the preparation process, and reduces the time and cost of screening nanobody sequences in the early stage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116478279B_ABST
    Figure CN116478279B_ABST
Patent Text Reader

Abstract

This invention provides a hepatitis B virus surface antigen (HBsAg) nanobody adsorbent, its preparation method, and its application. The HBsAg nanobody adsorbent is prepared by covalently coupling a single-domain antibody with the heavy chain variable region of an anti-HBsAg monoclonal antibody to an adsorbent carrier. The anti-HBsAg monoclonal antibody with the heavy chain variable region is obtained by optimizing the sequence of the variable region of the heavy chain of a humanized anti-HBsAg monoclonal antibody, preparing a recombinant vector, and then expressing it in *E. coli*. This HBsAg nanobody adsorbent, while ensuring efficient HBsAg clearance from plasma, significantly reduces the production cost of the ligand and substantially increases its potential for application in the field of HBsAg purification and adsorption, demonstrating great application potential and commercial value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of immunoadsorbent material preparation technology, and in particular to a hepatitis B virus surface antigen nanoantibody adsorbent, its preparation method, and its application. Background Technology

[0002] Hepatitis B virus (HBV) infection is a major pathogenic factor leading to hepatitis, cirrhosis, and liver cancer. Hepatitis B surface antigen (HBsAg) is abundant in the blood of HBV-infected individuals and is one of the markers of HBV infection. Given that hepatitis B cannot be completely cured, global treatment for hepatitis B currently only aims for functional cure, that is, effectively reducing HBsAg levels and restoring the body's immune system function, allowing patients to suppress HBV through their own immune system without long-term medication.

[0003] The applicant has been dedicated to the research and development of adsorbents for hepatitis B virus surface antigen. The adsorbent consists of a carrier and a ligand linked together chemically. Utilizing the principle of antigen-antibody specific binding between the ligand and HBsAg, the adsorbent removes the large amounts of HBsAg present in the blood of hepatitis B patients. Monoclonal antibodies possess high specificity and affinity, making them excellent ligands for hepatitis B virus surface antigen adsorbents.

[0004] However, in the existing technology, monoclonal antibodies must be generated by eukaryotic expression systems, and the culture of host cells requires high environmental requirements, resulting in high production costs for monoclonal antibodies. This has become a bottleneck for the commercialization of hepatitis B virus surface antigen adsorbents and even adsorption columns.

[0005] Alpaca serum contains a naturally occurring antibody lacking the light chain, known as a heavy chain antibody. Single-domain heavy chain antibodies are genetically engineered antibodies composed solely of the variable region of the heavy chain antibody; they are also called VHH antibodies or nanobodies. Compared to traditional antibodies, single-domain heavy chain antibodies can be prepared using prokaryotic expression systems, greatly simplifying the culture process and reducing production costs. They are an excellent ligand for adsorbing hepatitis B virus surface antigen.

[0006] In view of this, it is necessary to design an improved hepatitis B virus surface antigen nanobody adsorbent, its preparation method, and its application to solve the above problems. Summary of the Invention

[0007] The purpose of this invention is to provide a hepatitis B virus surface antigen nanobody adsorbent, its preparation method, and its application.

[0008] To achieve the above-mentioned objectives, this invention provides a hepatitis B virus surface antigen nanobody adsorbent, which is prepared by covalently coupling an anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibody to an adsorbent carrier.

[0009] The anti-HBsAg monoclonal antibody heavy chain variable region single domain antibody is obtained by site-directed mutation of the amino acid sequence of the heavy chain variable region of the anti-HBsAg humanized monoclonal antibody, optimization of the E. coli codon sequence of the mutated amino acid sequence, construction of a recombinant expression vector, and finally expression in E. coli.

[0010] The hepatitis B virus surface antigen nanoantibody adsorbent has an adsorption efficiency of over 90% for HBsAg in HBsAg-positive plasma.

[0011] As a further improvement of the present invention, the amino acid sequence of the anti-HBsAg monoclonal antibody heavy chain variable region single domain antibody is shown in SEQ ID NO.1;

[0012] As a further improvement of the present invention, the amino acid sequence of the anti-HBsAg monoclonal antibody heavy chain variable region single domain antibody is not limited to the sequence shown in SEQ ID NO.1. It can also be obtained by substituting and / or deleting one or more amino acid residues in the sequence shown in SEQ ID NO.1, and have the same biological activity as SEQ ID NO.1, such as the activity of specifically binding to hepatitis B surface antigen, or a derivative sequence with enhanced or weakened activity; such derivative sequences are also within the scope of protection of the present invention.

[0013] The amino acid sequence of the heavy chain variable region of the anti-HBsAg humanized monoclonal antibody is shown in SEQ ID NO.3.

[0014] As a further improvement of the present invention, during the process of optimizing the E. coli codon sequence, the nucleotide sequence of the optimized E. coli codon is shown in SEQ ID NO.2, which is used to encode the single-domain antibody of the heavy chain variable region of the anti-HBsAg monoclonal antibody.

[0015] As a further improvement of the present invention, the pGEX-6P-1 vector with GST tag is used for vector construction, and after obtaining the recombinant vector, it is expressed in Escherichia coli.

[0016] As a further improvement of the present invention, the ratio of the anti-HBsAg monoclonal antibody heavy chain variable region single domain antibody to the adsorbent carrier is (0.1-20) mg: 1 g.

[0017] As a further improvement of the present invention, the adsorbent carrier is one or a combination of agarose, cellulose, polystyrene, polyacrylamide, and polyvinyl alcohol.

[0018] To achieve the above-mentioned objective, the present invention also provides a method for preparing the above-mentioned hepatitis B virus surface antigen nanobody adsorbent, comprising the following steps:

[0019] S1, Sequence optimization: Using the amino acid sequence of the variable region of the heavy chain of the anti-HBsAg humanized monoclonal antibody (SEQ ID NO. 3) as the substrate, the 37V-44G-45L-47W mutation in the FR2 region of the anti-HBsAg humanized monoclonal antibody VH was changed to the 37Y-44E-45R-47G preferred by Cameloidea VHH, as shown in SEQ ID NO. 1; then, the codon sequence of E. coli was optimized to obtain the optimized codon of E. coli, the nucleotide sequence of which is shown in SEQ ID NO. 2, and then synthesized to obtain the synthetic gene;

[0020] S2, Vector construction: Using the synthesized gene sequence as a template, the target fragment is amplified to obtain the VHH gene; then, using the pGEX-6P-1 vector with the GST tag, the vector is subjected to double enzyme digestion, the VHH gene is subjected to homologous recombination with the double enzyme digested vector, the recombinant product is transformed and the positive clone is identified to obtain the recombinant expression vector.

[0021] S3, Preparation of single-domain antibody: The recombinant expression vector is transformed into an Escherichia coli expression strain to induce expression, and then the protein is purified to obtain nanobodies, which are anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibodies.

[0022] S4. The anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibody was used as a ligand and adsorbent carrier by chemical covalent coupling to prepare hepatitis B virus surface antigen nanobody adsorbent at a ratio of (0.1-20) mg: 1 g.

[0023] To achieve the above-mentioned objectives, this invention also provides the application of the above-mentioned hepatitis B virus surface antigen nanoantibody adsorbent in the field of hepatitis B virus purification and adsorption.

[0024] To achieve the above-mentioned objectives, this invention also provides a single-domain antibody against HBsAg monoclonal antibody heavy chain variable region, the amino acid sequence of which is shown in SEQ ID NO.1; its preparation method includes the following steps:

[0025] S1, Sequence optimization: Using the amino acid sequence of the variable region of the heavy chain of the anti-HBsAg humanized monoclonal antibody (SEQ ID NO.3) as the substrate, the 37V-44G-45L-47W mutation in the FR2 region of the anti-HBsAg humanized monoclonal antibody VH was changed to the 37Y-44E-45R-47G specific to the Camelidae VHH, and the amino acid sequence is shown in SEQ ID NO.1; then, the codon sequence of E. coli was optimized to obtain the optimized codon of E. coli, and its nucleotide sequence is shown in SEQ ID NO.2, which was then synthesized to obtain the synthetic gene;

[0026] S2, Vector construction: Using the synthesized gene sequence as a template, the target fragment is amplified to obtain the VHH gene; then, using the pGEX-6P-1 vector with the GST tag, the vector is subjected to double enzyme digestion, the VHH gene is subjected to homologous recombination with the double-digested vector, the recombinant product is transformed and the positive clone is identified to obtain the recombinant expression vector.

[0027] S3, Preparation of single-domain antibodies: The recombinant expression vector is transformed into an Escherichia coli expression strain for expression, and then the protein is purified to obtain nanobodies, which are anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibodies.

[0028] To achieve the above-mentioned objectives, this invention also provides the application of the above-mentioned anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibody in the preparation of hepatitis B virus purification and adsorption materials, the preparation of drugs for treating hepatitis B, and the preparation of hepatitis B surface antigen detection kits.

[0029] The beneficial effects of this invention are:

[0030] 1. The hepatitis B virus surface antigen nanobody adsorbent provided by this invention is composed of an anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibody and an adsorbent carrier coupled together. The anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibody prepared based on the Escherichia coli prokaryotic expression system retains the specificity of the anti-HBsAg monoclonal antibody. At the same time, the Escherichia coli expression system has the advantages of short fermentation cycle, easy cultivation, convenient operation, and easy scale-up, which greatly reduces the cost of ligands and increases the possibility of commercialization of the hepatitis B virus surface antigen nanobody adsorbent.

[0031] 2. The hepatitis B virus surface antigen nanobody provided by this invention is based on the variable region of the heavy chain of existing anti-HBsAg humanized monoclonal antibodies, with sequence optimization that maximizes the retention of antigen affinity, specificity, and low immunogenicity of anti-HBsAg humanized monoclonal antibodies. While ensuring the adsorption efficiency and safety of the adsorbent, it simultaneously enables the large-scale commercialization and low-cost preparation of this adsorbent.

[0032] 3. The method for preparing hepatitis B virus surface antigen nanobodies provided by this invention utilizes a pGEX-6P-1 vector with a GST tag, which can prepare nanobodies primarily due to the good solubility of GST. The fusion expression of GST and nanobodies can improve the solubility of the nanobodies. Furthermore, compared to the existing method of preparing nanobodies using alpaca immunization, which has technical drawbacks such as complex processes, long cycles, and high costs, this application uses a method of sequence optimization of the variable region of the heavy chain of a known anti-HBsAg humanized monoclonal antibody, significantly saving time and cost in the early screening of nanobodily antibody sequences. This nanobodily antibody preparation process is simple (monoclonal antibody VH sequence—VHH exogenous expression in E. coli), and nanobodies can be prepared based on known monoclonal antibody sequences, greatly saving time and cost in the early screening of nanobodily antibody sequences and simplifying the preparation process. The method adopted in this invention is of reference value for preparing corresponding nanobodies from other known monoclonal antibody sequences. Attached Figure Description

[0033] Figure 1 The results of SDS-PAGE electrophoresis of the anti-HBsAg monoclonal antibody heavy chain variable region single domain antibody provided in Example 1 of this invention are shown. Detailed Implementation

[0034] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be described in detail below with reference to the accompanying drawings and specific embodiments.

[0035] It should also be noted that, in order to avoid obscuring the present invention with unnecessary details, only the structures and / or processing steps closely related to the present invention are shown in the accompanying drawings, while other details that are not closely related to the present invention are omitted.

[0036] Additionally, it should be noted that the terms “comprising,” “including,” or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.

[0037] This invention provides a method for preparing a hepatitis B virus surface antigen nanobody adsorbent, comprising the following steps:

[0038] S1, Sequence optimization: Using the amino acid sequence of the variable region of the heavy chain of the anti-HBsAg humanized monoclonal antibody (SEQ ID NO.3) as the substrate, the 37V-44G-45L-47W mutation in the FR2 region of the anti-HBsAg humanized monoclonal antibody VH was changed to the 37Y-44E-45R-47G specific to the Camelidae VHH, and the amino acid sequence is shown in SEQ ID NO.1; then, the codon sequence of E. coli was optimized to obtain the optimized codon of E. coli, and its nucleotide sequence is shown in SEQ ID NO.2, which was then synthesized to obtain the synthetic gene;

[0039] S2, Vector construction: Using the synthesized gene sequence as a template, the target fragment is amplified to obtain the VHH gene; then, using the pGEX-6P-1 vector with the GST tag, the vector is subjected to double enzyme digestion, the VHH gene is subjected to homologous recombination with the double enzyme digested vector, the recombinant product is transformed and the positive clone is identified to obtain the recombinant expression vector.

[0040] S3, Preparation of single-domain antibody: The recombinant expression vector is transformed into an Escherichia coli expression strain to induce expression, and then the protein is purified to obtain nanobodies, which are anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibodies.

[0041] S4. The anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibody was used as a ligand and adsorbent carrier by chemical covalent coupling to prepare hepatitis B virus surface antigen nanobody adsorbent at a ratio of (0.1-20) mg: 1 g.

[0042] In this invention, the heavy chain variable region sequence of the anti-HBsAg humanized monoclonal antibody provided in the invention patent application No. 202111395172X (Hepatitis B virus surface antigen adsorbent and its application) is used as the existing substrate of this invention. Its amino acid sequence is 116aa long and the sequence is shown in SEQ ID NO.3.

[0043] The following is a detailed explanation of the humanized monoclonal antibody against HBsAg:

[0044] This humanized anti-HBsAg monoclonal antibody was developed by modifying a murine anti-HBsAg monoclonal antibody using a CDR (complementarity-determining region) transplantation method. The amino acid sequence of the heavy chain variable region VH of this humanized anti-HBsAg monoclonal antibody is shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region VL is shown in SEQ ID NO.4.

[0045] Furthermore, the anti-HBsAg murine monoclonal antibody was prepared using hybridoma technology; the amino acid sequence of the heavy chain variable region VH of the anti-HBsAg murine monoclonal antibody is shown in SEQ ID NO. 5 (the gene sequence encoding the heavy chain variable region is 348 bp long, and based on the obtained gene sequence, it is deduced that the heavy chain variable region encoded by this gene sequence consists of 116 amino acids). The amino acid sequence of the light chain variable region VL of the anti-HBsAg murine monoclonal antibody is shown in SEQ ID NO. 6 (the gene sequence encoding the light chain variable region is 321 bp long, and based on the obtained gene sequence, it is deduced that the light chain variable region encoded by this gene sequence consists of 107 amino acids).

[0046] Furthermore, the specific preparation process of this anti-HBsAg humanized monoclonal antibody is as follows:

[0047] 1. Antibody Humanization: Based on sequence similarity and conformational clustering analysis, antibody modeling is performed, and a suitable germline sequence is selected for CDR transplantation. The variable regions of the humanized heavy and light chains are fused with the constant regions of the heavy and light chains of human IgG1κ to form complete heavy and light chains, thus constructing humanized antibodies.

[0048] 2. Comparison of humanized antibody expression levels: A recombinant plasmid containing a humanized antibody gene was constructed and transfected into HEK-293E cells for serum-free suspension culture to transiently express humanized antibodies.

[0049] 3. Detection of binding activity between humanized antibodies and HBsAg: The half-maximal effective concentration (EC50) was determined using an indirect ELISA method. 50 To evaluate the binding ability of humanized monoclonal antibodies against HBsAg to HBsAg.

[0050] The following specific embodiments further illustrate the hepatitis B virus surface antigen nanoantibody adsorbent provided by the present invention.

[0051] Example 1

[0052] Example 1 of this invention provides a method for preparing a hepatitis B virus surface antigen nanobody adsorbent, comprising the following steps:

[0053] S1, Sequence Optimization

[0054] The heavy chain variable region sequence of the anti-HBsAg humanized monoclonal antibody provided in the invention patent application number 202111395172X (Hepatitis B virus surface antigen adsorbent and its application) is used as the existing base material of this invention. Its amino acid sequence is 116 aa long, as shown in SEQ ID NO.3. Based on the characteristics of camel-derived VHH, the 37V-44G-45L-47W mutation in the FR2 region of the anti-HBsAg humanized monoclonal antibody VH is mutated to the 37Y-44E-45R-47G specific to camel-derived VHH, with an amino acid sequence length of 116 aa, as shown in SEQ ID NO.1. The mutation position is shown underlined below:

[0055] (SEQ ID NO.1: QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWMHW Y RQAPGQ ER E G MGDIHPGGGNTKYNQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARHGHYFDYWGQGTLVTVSS

[0056] SEQ ID NO.3:

[0057] QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWMHW V RQAPGQ GL E W MGDIHPGGGNTKYNQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARHGHYFDYWGQGTLVTVSS)

[0058] Based on the codon preference of *E. coli*, codon sequence optimization was performed, resulting in a 354 bp nucleic acid sequence, as shown in SEQ ID NO.2. This SEQ ID NO.2 sequence was then sent to a biotechnology company for synthesis, yielding the synthetic group.

[0059] Construction of S2, pGEX-6P-1 genetically engineered bacteria

[0060] (1) Amplification of the target fragment

[0061] Using the synthesized gene sequence as a template and F and R as primers, PCR amplification was performed to obtain the single-domain antibody gene of the heavy chain variable region of anti-HBsAg monoclonal antibody, namely the VHH gene.

[0062] The PCR amplification program was as follows: pre-denaturation 95℃-5min; denaturation 95℃-30s, annealing 58℃-30s, extension 68℃-15s for a total of 34 cycles; and total extension 68℃-10min.

[0063] F: TTCCAGGGGCCCCTGGGATCC ATGCAGGTTCAGCTGGTTCAG

[0064] R: GTCACGATGCGGCCGCTCGAG TTAAGAAGAAACGGTAACCAGGGT

[0065] The PCR amplification system is as follows:

[0066] Components Sample volume template cDNA 100ng F / R primers (10 μmol / L) 1μL 10×Buffer for KOD 5μL 2mM dNTPs 5μL 25mM MgSO4 3μL KOD 1μL <![CDATA[ddH2O]]> Up to 50μL

[0067] The primer sequences are shown above, with the underlined portion indicating the homologous arm of the vector pGEX-6P-1. The obtained PCR product was separated and excised by 1% agarose gel electrophoresis, and the 354bp target DNA fragment was recovered using a DNA agarose gel purification kit.

[0068] (2) Vector double enzyme digestion treatment

[0069] The reaction solution was prepared using the pGEX-6P-1 carrier with a GST tag according to the following system:

[0070] Components Sample volume pGEX-6P-1 vector 4μg BamHI 2μL XhoI 2μL 10×CutsmartBuffer 3μL <![CDATA[ddH2O]]> Up to 30μL

[0071] Incubate at 37°C for 2 hours, then purify the vector using a DNA purification kit.

[0072] (3) Homologous recombination of the VHH gene with the double-enzyme-digested pGEX-6P-1 vector was performed.

[0073] Novozymes The II One Step Cloning Kit system is as follows:

[0074] Components Sample volume pGEX-6P-1 double enzyme digestion vector 100ng VHH gene fragment 50ng 5×CEIIBuffer 4μL Exnase II 2μL <![CDATA[ddH2O]]> Up to 20μL

[0075] Gently mix the mixture using a pipette, and briefly centrifuge to collect the reaction solution at the bottom of the tube. After reacting at 37°C for 30 minutes, immediately place the tube on ice to cool, thus obtaining the recombinant product.

[0076] (4) Transformation of recombinant products

[0077] a. Thaw the Top10 competent cells on ice, add 10 μL of recombinant product to 100 μL of competent cells, gently tap the tube wall to mix, and let stand on ice for 30 min.

[0078] b. After heat shock in a 42℃ water bath for 45 seconds, immediately place it on ice to cool for 2-3 minutes.

[0079] c. Add 900 μL of LB medium and shake at 37℃-220 r / min for 1 h.

[0080] d. Preheat the ampicillin-resistant LB solid medium plates in a 37°C incubator.

[0081] Centrifuge at 5000 rpm for 5 min and discard 900 μL of supernatant. Resuspend the bacterial cells in the remaining culture medium, spread evenly with a sterile spreader, and incubate upside down in a 37°C incubator for 12-16 h to obtain the recombinant plasmid VHH-pGEX-6P-1.

[0082] (5) Identification of positive clones

[0083] Select a single clone, shake it for 12-16 hours, extract plasmids, and sequence it.

[0084] S3, Preparation of anti-HBsAg monoclonal antibody heavy chain variable region single domain antibody

[0085] (1) Induced expression

[0086] a. Transform the recombinant plasmid VHH-pGEX-6P-1 into Escherichia coli BL21 expression strains, pick single clones and inoculate them into 4 mL LB medium, and culture at 37℃ and 250 r / min for 4-5 h.

[0087] b. Inoculate 1% (V / V) into 100 mL LB medium and incubate at 37°C and 250 rpm until OD. 600 Approximately 0.8.

[0088] c. Add IPTG to a final concentration of 0.1 mM, and induce overnight at 18°C ​​and 220 r / min.

[0089] Centrifuge at 12000 r / min for 10 min, discard the supernatant, and collect the bacterial cells.

[0090] e. Take the above bacteria and resuspend them in sonication buffer (50mM Tris-HCl, 400mM Nacl, 2.5mM EDTA, pH 8.0).

[0091] f. Ultrasonic disruption of bacterial cells. Ultrasonic conditions: 25-35 min, 5 s intervals with 10 s intervals, 200 W power.

[0092] Centrifuge at 12000 r / min at 4℃ for 20 min, and carefully remove the supernatant.

[0093] (2) Protein purification

[0094] a. Inclusion bodies are suspended in a certain amount of washing buffer (2M Urea, 50mM Tris-HCl, 400mM NaCl, 2.5mM EDTA, 0.5% Triton X-100, pH 8.0), centrifuged at 10000 rpm for 10 min at 4℃, and the inclusion bodies are collected. The washing process is repeated 3-6 times. The supernatant is discarded, and the residual liquid is aspirated by inverting the container.

[0095] b. The precipitate was suspended in lysis buffer (8M Urea, 50mM Tris-HCl, 400mM NaCl, 2.5mM EDTA, pH 8.0) and allowed to dissolve completely at room temperature for 3 hours. The precipitate was then centrifuged at 11000 rpm for 10 minutes at 4°C, and the supernatant was collected.

[0096] c. Transfer the supernatant into a dialysis bag, and the concentration of Urea in the dialysis solution decreases gradually: 8M-6M-4M-2M-PBS.

[0097] d. Collect the sample solution in the dialysis bag, centrifuge at 10000 r / min for 10 min at 4℃, collect the supernatant, and pass the supernatant through a 0.45 μm membrane.

[0098] e. Add 5-10 column volumes of ultrapure water to rinse the GST column.

[0099] f. Add 5-10 column volumes of equilibration buffer (50mM HEPES + 400mM Nacl) to equilibrate the column.

[0100] g. The sample with the 0.45 μm membrane added was added to the GST column and incubated at 4 °C for 4 h.

[0101] h. Add 5-10 column volumes of equilibration buffer (50mM HEPES + 400mM NaCl) to elute impurities.

[0102] i. Add GST-3C to the equilibration buffer (50mM HEPES + 400mM NaCl) and incubate overnight at 4°C for enzyme digestion.

[0103] j. Elute the nanobody with 2-3 column volumes of elution buffer (50 mM HEPES + 150 mM Nacl) and concentrate using a 3 kDa ultrafiltration tube.

[0104] The results are as follows: The nanobody expressed on the VHH-pGEX-6P-1 vector formed inclusion bodies, which, after denaturation and renaturation, formed a soluble protein. SDS-PAGE analysis showed the target protein size to be approximately 13 kDa, close to the theoretical molecular weight. Figure 1 As shown.

[0105] S4, Preparation and Adsorption Performance Testing of Hepatitis B Virus Surface Antigen Nanobody Adsorbent

[0106] Prepare a single-domain heavy chain variable region antibody against HBsAg using the VHH-pGEX-6P-1 vector and agarose microspheres. Coupling the ligand and vector at a ratio of 3 mg:1 g via chemical conjugation yields the hepatitis B virus surface antigen nanobody adsorbent. (Note: The above ratio can be adjusted according to actual application requirements.)

[0107] The adsorbent was rinsed with physiological saline, and then a certain mass of adsorbent was weighed into a centrifuge tube. A certain proportion of HBsAg positive plasma was added, and the tube was placed on a shaker at 37℃ and shaken at 120 rpm for 2 hours. After the adsorbent settled naturally for 30 minutes, the supernatant was collected for testing.

[0108] The HBsAg content in plasma before and after adsorption was determined using a fully automated biochemical analyzer to ascertain the adsorption efficiency. The results are shown in Table 1.

[0109] Table 1 shows the adsorption efficiency of the hepatitis B virus surface antigen nanobody adsorbent prepared in Example 1 for HBsAg.

[0110]

[0111] Table 1 shows that the hepatitis B virus surface antigen nanobody adsorbent provided by this invention exhibits excellent adsorption performance for HBsAg under shaker conditions. The adsorbent prepared from the single-domain antibody of the heavy chain variable region of anti-HBsAg monoclonal antibody achieves an adsorption rate of 92.36% for HBsAg.

[0112] Comparative Example 1

[0113] The difference from Example 1 is that pET-28a(+) with the His tag is used as the vector in the S2 vector construction process. Everything else is the same as in Example 1, and will not be repeated here.

[0114] The specific steps of S2 are as follows:

[0115] Construction of S2, pET-28a(+) genetically engineered bacteria

[0116] (1) Amplification of the target fragment

[0117] Using the synthesized gene sequence as a template and F and R as primers, PCR amplification was performed to obtain the monoclonal antibody variable region gene, namely the VHH gene. The PCR amplification system is as follows:

[0118] Components Sample volume template cDNA 100ng F / R primers (10 μmol / L) 1μL 10×Buffer for KOD 5μL 2mM dNTPs 5μL <![CDATA[25mM MgSO4]]> 3μL KOD 1μL <![CDATA[ddH2O]]> Up to 50μL

[0119] The PCR amplification program was as follows: pre-denaturation 95℃-5min; denaturation 95℃-30s, annealing 58℃-30s, extension 68℃-15s, for a total of 34 cycles; total extension 68℃-10min.

[0120] F: AATCTTTATTTTCAGGGCCGGCCA ATGCAGGTTCAGCTGGTTCA

[0121] R: TCGAATTCGGATCCTGGCGCGCC TTAAGAAGAAACGGTAACCAGGGT

[0122] The primer sequences are shown above, with the underlined portion indicating the homologous arm of the vector pET-28a(+). The obtained PCR product was separated and excised by 1% agarose gel electrophoresis, and the 354bp target DNA fragment was recovered using a DNA agarose gel purification kit.

[0123] (2) Vector double enzyme digestion treatment

[0124] Prepare the reaction solution according to the following system:

[0125] Components Sample volume pET-28a(+) vector 4μg ikB 2μL AscI 2μL 10×CutsmartBuffer 3μL <![CDATA[ddH2O]]> Up to 30μL

[0126] Incubate at 37°C for 2 hours, then purify the vector using a DNA purification kit.

[0127] (3) Homologous recombination of the VHH gene with the double-enzyme-digested pET-28a(+) vector was performed.

[0128] Novozymes The II One Step Cloning Kit system is as follows:

[0129] Components Sample volume pET-28a(FseI / AscI) 100ng VHH gene fragment 50ng 5×CEIIBuffer 4μL Exnase II 2μL <![CDATA[ddH2O]]> Up to 20μL

[0130] Gently mix the mixture using a pipette, and briefly centrifuge to collect the reaction solution at the bottom of the tube. After reacting at 37°C for 30 minutes, immediately place the tube on ice to cool, thus obtaining the recombinant product.

[0131] (4) Transformation of recombinant products

[0132] Thaw the Top 10 competent cells on ice, add 10 μL of recombinant product to 100 μL of competent cells, gently tap the tube wall to mix, and let stand on ice for 30 min.

[0133] • After heat shock in a 42℃ water bath for 45 seconds, immediately place it on ice to cool for 2-3 minutes.

[0134] Add 900 μL of LB medium and shake at 37℃-220 r / min for 1 h.

[0135] Preheat the kanamycin-resistant LB solid medium plates in a 37°C incubator.

[0136] Centrifuge at 5000 rpm for 5 min and discard 900 μL of supernatant. Resuspend the bacterial cells in the remaining culture medium, spread evenly with a sterile spreader, and incubate upside down in a 37°C incubator for 12-16 h to obtain recombinant plasmid VHH-pET-28a(+).

[0137] (5) Identification of positive clones

[0138] Select single clones and shake for 12-16 hours, then extract plasmids and perform sequencing and alignment.

[0139] After further expression in E. coli in step S3, nanobodies expressed on the VHH-pET-28a(+) vector were obtained.

[0140] The results are as follows: the nanobody expressed on the VHH-pET-28a(+) vector formed inclusion bodies, which precipitated after refolding and could not form soluble protein. That is, Comparative Example 1, using the His-tagged pET-28a(+) vector, could not yield soluble anti-HBsAg monoclonal antibody heavy chain variable region single-domain antibody.

[0141] The above indicates that the GST-tagged pGEX-6P-1 vector used in Example 1 successfully prepared soluble nanobodies, but the His-tagged pET-28a(+) vector used in Comparative Example 1 failed to prepare soluble nanobodies. This is mainly because the better water solubility of GST improves the hydrophilicity of the single-domain antibody in the variable region of the heavy chain of the anti-HBsAg monoclonal antibody.

[0142] In summary, this invention provides a hepatitis B virus surface antigen (HBV) nanobody adsorbent, its preparation method, and its application. The HBV Surface Antigen Nanobody Adsorbent is prepared by covalently coupling a single-domain antibody of the heavy chain variable region of an anti-HBsAg monoclonal antibody to an adsorbent carrier. The anti-HBsAg monoclonal antibody of the heavy chain variable region is obtained by sequence optimization of the gene of the humanized anti-HBsAg monoclonal antibody heavy chain variable region, preparation of a recombinant vector, and expression in *E. coli*. The HBV Surface Antigen Nanobody Adsorbent achieves an adsorption efficiency of over 90% for HBsAg-positive plasma. This HBV Surface Antigen Nanobody Adsorbent, while ensuring efficient HBsAg clearance from plasma, significantly reduces the production cost of the ligand, substantially increasing its potential for application in the field of HBV purification and adsorption, and possesses significant application potential and commercial value.

[0143] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

[0144] SEQ ID NO.1

[0145] QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWMHW Y RQAPGQ ER E G MGDIHPGGGNTKYNQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARHGHYFDYWGQGTLVTVSS

[0146] SEQ ID NO.2

[0147] ATGCAGGTTCAGCTGGTTCAGTCTGGTGCTGAAGTTAAAAAACCGGGTGCTTCTGTTAAAGTTTCTTGCAAAGCTTCTGGTTACACCTTCTCTACCTACTGGATGCACTGGTACCGTCAGGCTCCGGGTCAGGAACGTGAAGGTATGGGTGACATCCACCCGGGTGGTGGTAACACC AAATACAACCAGAAATTCCAGGGTCGTGTTACCATCACCCGTGACACCTCTGCTTCTACCGCTTACATGGAACTGTCTTCTCTGCGTTCTGAAGACACCGCTGTTTACTACTGCGCTCGTCACGGTCACTACTTCGACTACTGGGGTCAGGGTAACCCTGGTTACCGTTTCTTCTTAA

[0148] SEQ ID NO.3

[0149] QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWMHW V RQAPGQ GL E W MGDIHPGGGNTKYNQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCARHGHYFDYWGQGTLVTVSS

[0150] SEQ ID NO.4

[0151] DIQMTQSPSSSLSASVGDRVTITCRASQDISNYLNWYQQKPGGAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGDTLPFTFPGGTKVDIK

[0152] SEQ ID NO.5

[0153] QVQLQQPGAELVRPGASVKLSCKASGYTFSTYWMHWVKQRPGQGLEWIGDIHPGGGNTYYNERFKRKASLTVDTSSNTAYMQLSSLTSEDSAVYYCARHGHYFDYWGQGTTITVSS

[0154] SEQ ID NO.6

[0155] DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGSVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTIANLEQEDIATYFCQQGDTLPFTFGSGTKLEIK sequence list <110> Wuhan Ruifa Medical Equipment Co., Ltd. <120> Hepatitis B virus surface antigen nanobody adsorbent, its preparation method and application <141> 2021-12-31 <160> 6 <170> SIPOSequenceListing 1.0 <210> 1 <211> 116 <212> PRT <213> Artificial Sequence <400> 1 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr Tyr 20 25 30 Trp Met His Trp Tyr Arg Gln Ala Pro Gly Gln Glu Arg Glu Gly Met 35 40 45 Gly Asp Ile His Pro Gly Gly Gly Asn Thr Lys Tyr Asn Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Gly His Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 2 <211> 354 <212> DNA <213> Artificial Sequence <400> 2 atgcaggttc agctggttca gtctggtgct gaagttaaaa aaccgggtgc ttctgttaaa 60 gtttcttgca aagcttctgg ttacaccttc tctacctact ggatgcactg gtaccgtcag 120 gctccgggtc aggaacgtga aggtatgggt gacatccacc cgggtggtgg taacaccaaa 180 tacaaccaga aattccaggg tcgtgttacc atcacccgtg acacctctgc ttctaccgct 240 tacatggaac tgtcttctct gcgttctgaa gacaccgctg tttactactg cgctcgtcac 300 ggtcactact tcgactactg gggtcagggt accctggtta ccgtttcttc ttaa 354 <210> 3 <211> 116 <212> PRT <213> Artificial Sequence <400> 3 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Asp Ile His Pro Gly Gly Gly Asn Thr Lys Tyr Asn Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Gly His Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 4 <211> 107 <212> PRT <213> Artificial Sequence <400> 4 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gly Ala Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asp Thr Leu Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 5 <211> 116 <212> PRT <213> Artificial Sequence <400> 5 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Thr Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Ile His Pro Gly Gly Gly Asn Thr Tyr Tyr Asn Glu Arg Phe 50 55 60 Lys Arg Lys Ala Ser Leu Thr Val Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Gly His Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Ile 100 105 110 Thr Val Ser Ser 115 <210> 6 <211> 107 <212> PRT <213> Artificial Sequence <400> 6 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Ser Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ala Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asp Thr Leu Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105

Claims

1. A hepatitis B virus surface antigen nanobody adsorbent, characterized in that: The hepatitis B virus surface antigen nanobody adsorbent is prepared by covalently coupling an anti-HBsAg single-domain antibody to an adsorbent carrier; the amino acid sequence of the anti-HBsAg single-domain antibody is shown in SEQ ID NO.

1. The anti-HBsAg single-domain antibody was obtained by site-directed mutation of the amino acid sequence of the variable region of the heavy chain of the anti-HBsAg humanized monoclonal antibody, optimization of the mutated amino acid sequence with E. coli codons, construction of a recombinant expression vector, and finally expression in E. coli. The hepatitis B virus surface antigen nanoantibody adsorbent has an adsorption efficiency of over 90% for HBsAg in HBsAg-positive plasma.

2. The hepatitis B virus surface antigen nanobody adsorbent according to claim 1, characterized in that: During the optimization of the E. coli codon sequence, the nucleotide sequence of the optimized E. coli codon is shown in SEQ ID NO.2, which is used to encode the anti-HBsAg single-domain antibody.

3. The hepatitis B virus surface antigen nanobody adsorbent according to claim 1, characterized in that: The recombinant expression vector was constructed using the pGEX-6P-1 vector with the GST tag, and then expressed in Escherichia coli.

4. The hepatitis B virus surface antigen nanobody adsorbent according to claim 1, characterized in that: The ratio of the anti-HBsAg single-domain antibody to the adsorbent carrier is (0.1-20) mg: 1 g.

5. The hepatitis B virus surface antigen nanobody adsorbent according to claim 1, characterized in that: The adsorbent carrier is one or a combination of agarose, cellulose, polystyrene, polyacrylamide, and polyvinyl alcohol.

6. A method for preparing the hepatitis B virus surface antigen nanobody adsorbent according to any one of claims 1-5, characterized in that: Includes the following steps: S1, Sequence optimization: Using the amino acid sequence of the heavy chain variable region of the anti-HBsAg humanized monoclonal antibody (SEQ ID NO.3) as the substrate, the 37V-44G-45L-47W mutation in the FR2 region of the anti-HBsAg humanized monoclonal antibody VH was changed to the 37Y-44E-45R-47G preferred by Cameloidea VHH, and the amino acid sequence is shown in SEQ ID NO.1; then, the codon sequence of E. coli was optimized to obtain the optimized codon of E. coli, and its nucleotide sequence is shown in SEQ ID NO.2, which was then synthesized to obtain the synthetic gene; S2, Vector construction: Using the synthesized gene sequence as a template, the target fragment is amplified to obtain the VHH gene; then, using the pGEX-6P-1 vector with the GST tag, the vector is subjected to double enzyme digestion, the VHH gene is subjected to homologous recombination with the double enzyme digested vector, the recombinant product is transformed and the positive clone is identified to obtain the recombinant expression vector. S3, Preparation of single-domain antibodies: The recombinant expression vector is transformed into an Escherichia coli expression strain for expression, and then the protein is purified to obtain nanobodies, which are anti-HBsAg single-domain antibodies; S4, using the anti-HBsAg single-domain antibody as a ligand, the ligand and the adsorbent carrier are covalently coupled by chemical method at a ratio of (0.1-20) mg: 1 g to prepare a hepatitis B virus surface antigen nanobody adsorbent.

7. A single-domain antibody against HBsAg, characterized in that: The amino acid sequence of the anti-HBsAg single-domain antibody is shown in SEQ ID NO.

1.

8. The application of the anti-HBsAg single-domain antibody according to claim 7, characterized in that: The application of the anti-HBsAg single-domain antibody in the preparation of hepatitis B virus purification and adsorption materials and in the preparation of hepatitis B surface antigen detection kits.

Citation Information

Patent Citations

  • Hepatitis B virus surface antigen adsorbent and application thereof

    CN114195887A